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Abstract: Acute promyelocytic leukemia (APL) has two morphological variants, namely macrogranular (M3) and mi-
crogranular (M3v). M3v, characterized by the presence of neoplastic promyelocytes with only sparse fine azurophilic 
granules, accounts for 10-25% of all APL and has unique biological characteristics. Relapse occurs in approximately 
20% of patients with APL. The morphological type of the leukemic cells at relapse is usually identical with the pri-
mary disease, and only one case of morphological change at relapse has been reported. Here, we analyzed the 
clinicopathological features of APL, including 4 relapsed cases emphasizing morphological changes at the time of 
relapse. The unique finding of the present study is that 2 of 4 relapsed cases changed from M3 to M3v at relapse. 
The morphological features of these were different in each case (one had blastic features and the other resembled 
monocytoid leukemic cells). Cytogenetic analyses revealed the continued presence of t(15;17)(q22;q12) at the time 
of relapse and morphological change. Moreover, the immune phenotype of the leukemic cells changed from CD2-/
CD34- to CD2+/CD34+ at that time. These findings suggest that morphological change at relapse in APL may not be 
a rare event, and that the leukemic cells can show variable morphological features at the time of relapse, which 
could result in misdiagnosis as a different type of acute myeloid leukemia. Therefore, a comprehensive approach 
with emphasis on combined morphological, immunophenotypic, and cytogenetic analyses is important for diagnosis 
and appropriate treatment of relapsed APL.
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Introduction
Acute promyelocytic leukemia (APL) is a distinct 
subtype of acute myeloid leukemia (AML) with 
characteristic clinical and molecular features, 
and accounts for 5-8% of all cases of AML. It is 
well known that APL has two morphological 
variants, namely macrogranular (M3) and 
microgranular (M3v) [1]. M3v accounts for 
approximately 10-25% of adult APL cases and 
perhaps a somewhat higher fraction in chil-
dren, and has unique biological characteristics, 
such as a higher white blood cell count at pre-
sentation, and frequent expression of CD2 and 
CD34 [2-5]. This variant is characterized mor-
phologically by the presence of neoplastic pro-
myelocytes with only sparse fine azurophilic 
granules and infrequent Auer rods, or no gran-
ules and containing a bi-lobed, multi-lobed, or 
reniform nucleus [6].
Despite the success of current therapies for 
APL, relapse still occurs in approximately 20% 
of patients. The morphological and immuno-
phenotypic characteristics of APL at the time of 
relapse have not been well-documented, 
although recently Dimov et al. analyzed 38 
cases of relapsed APL [7]. Herein, we analyzed 
the clinicopathological features of 12 consecu-
tive cases of APL including 4 relapsed cases in 
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our institute; we discuss the morphological and 
immunophenotypic features, especially in the 
relapsed cases.
Materials and methods
This retrospective study included 12 consecu-
tive APL cases treated at the Department of 
Hematology of Shiga University of Medical 
Science from 1993 to 2012. All cases of APL 
were confirmed by the presence of t(15;17)
(q22;q12) identified by conventional cytogenet-
ic analysis. All cases were morphologically clas-
sified according to the French-American-British 
(FAB) classification.
Flow cytometric immune phenotyping analyses 
on bone marrow aspirates were performed 
using a FACSCalibur flow cytometer (Becton 
Dickinson Biosciences, San Jose, CA, USA). The 
panel of monoclonal antibodies used in this 
study included CD2, CD3, CD4, CD5, CD7, CD8, 
CD10, CD13, CD14, CD15, CD19, CD20, CD25, 
CD33, CD34, CD38, CD45, CD56, and HLA-DR. 
These antibodies were purchased from Becton 
Dickinson Biosciences. For this study, a marker 
was considered positive if expressed by more 
than 20% of the analyzed cells. 
The risk of relapse in APL cases was estab-
lished at initial diagnosis according to the previ-
ously reported predictive model based on 
peripheral blood leukocyte and platelet counts 
[8]. Low-risk patients had a leukocyte count 
≤10 × 109 /L and a platelet count >40 × 109 /L; 
intermediate-risk patients had a leukocyte 
count ≤10 × 109 /L and a platelet count ≤40 × 
109 /L; and high-risk patients had a leukocyte 
count >10 × 109 /L. 
Results
Patients’ characteristics
Table 1 summarizes the clinical features of 
these APL cases at initial diagnosis. There were 
4 males and 8 females of ages ranging from 15 
to 64 years (mean 46.3 years). This study 
included 3 patients at high risk of relapse (2 
cases had relapsed and the other was M3v), 4 
intermediate relapse risk (one relapsed and 3 
in complete remission (CR)), and 5 cases at low 
risk of relapse (one relapsed and 4 in CR). 
All patients except Case 12 were treated with 
all-trans-retinoic acid (ATRA) plus chemoth- 
erapy. 
Clinical outcome
In the four cases of M3 with relapse (Cases 
1-4), Cases 1 and 2 had one relapse, Case 3 
had two relapses, and Case 4 had three relaps-
es. Case 1 had a skin relapse without bone 
marrow involvement, and the other 3 cases had 
relapses only in the bone marrow. Cases 1 and 
2 died of disease progression, and Case 4 
remains alive without progression 8 months 
after the third relapse. The fate of Case 3 is not 
known. The continued presence of t(15;17)
(q22;q12) was confirmed at every time of 
relapse in these cases. 
In the seven cases of M3 in complete remission 
(Cases 5-11), 5 remain alive in CR. Case 10 
developed myelodysplastic syndrome (MDS) 
after ATRA combined chemotherapy, resulting 
in death on disease progression into AML. In 
this patient, the leukemic cells after ATRA ther-
apy were CD34+/HLA-DR+ and lacked t(15;17)
(q22;q12). Therefore, this case was considered 
as a therapy-related myeloid neoplasm (t-MN). 
Case 11 died of liver cirrhosis. 
The M3v patient (Case 12) died of brain hemor-
rhage immediately after the diagnosis, before 
treatment could be initiated. 
Morphological characteristics
In Cases 1-11, the leukemic cells at initial diag-
nosis showed typical features of macrogranular 
neoplastic promyelocytes. They had bi-lobed or 
folded nuclei and abundant cytoplasm with 
large granules (Figure 1A). In Case 12, the leu-
kemic cells at initial diagnosis had bi-lobed or 
multi-lobed nuclei and only sparse fine azuro-
philic granules and infrequent Auer rods, or no 
granules (Figure 1B), which are characteristic 
features of M3v. 
In Cases 3 and 4, the morphology of the leuke-
mic cells changed from typical macrogranular 
type to microgranular variant at relapse (Table 
2). The leukemic cells at the second relapse of 
Case 3 had a high nuclear/cytoplasmic ratio, 
scant cytoplasm, and irregular nuclear con-
tours. The cytoplasm of these cells contained 
no granules, although small vacuoles were 
present in some of them (Figure 1C). The leuke-
mic cells at the third relapse of Case 4 had a 
small amount of cytoplasm and irregular nucle-
ar contours, and contained no granules (Figure 
1D). 
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Table 1. Clinical features of acute promyelocytic leukemia
Case No. Age Gender
Leukocytes Platelet Relapse
Treatment Outcome
(× 109 /L) (× 109 /L) Risk
Group I (M3 with relapse)
1 15 Female 26.2 1.1 High ATRA combined with chemotherapy Died of disease progression
2 64 Male 0.5 3.6 Intermediate APL92 Died of disease progression
3 49 Female 15.2 3.1 High APL97 Not available
4 59 Female 0.8 6.6 Low APL97 Alive without progression
Group II (M3 with complete remission)
5 31 Female 1 7.7 Low APL92 Alive in complete remission
6 34 Female 0.5 2.1 Intermediate APL97 Alive in complete remission
7 55 Female 1 0.6 Intermediate APL97 Alive in complete remission
8 34 Female 3 1.7 Intermediate APL204 Alive in complete remission
9 51 Male 0.8 14.8 Low APL204 Alive in complete remission
10 58 Male 2.2 15.5 Low APL97 Died of treatment-related myeloid neoplasm
11 58 Male 2.8 9.6 Low APL92 Died of liver cirrhosis
Group III (M3v)
12 48 Female 147 1.8 High Not Done Died of brain hemorrhage
ATRA, all-trans-retinoic acid.
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Immunophenotypic characteristics
Table 2 summarizes the immunophenotyping 
of these APL cases. The data at initial diagnosis 
(Case 1), the first relapse (Case 2), and initial 
and subsequent relapse (the second and third 
time in Cases 3 and 4, respectively) were avail-
able for relapsed M3. They were also available 
for all M3 cases in CR (Cases 5-11) and M3v 
(Case 12).
CD2 and CD34 were expressed by the leukemic 
cells in Case 1, and CD2 expression was also 
noted in Case 12 at initial diagnosis. However, 
these markers were not expressed in any of the 
other cases at initial diagnosis. CD56 expres-
sion was observed in Case 2 (at the first 
relapse) and Case 12. Intriguingly, the expres-
sion of CD2 and CD34 was seen in those cases 
showing morphological changes at relapse 
(Cases 3 and 4). In both cases, at the initial 
diagnosis, the leukemic cells showed the typi-
cal morphology of macrogranular promyelo-
cytes and were CD2-/CD34-. However, the leu-
kemic cells showing microgranular morphology 
at the time of relapse were CD2+/CD34+. In 
addition, both cases also gain CD56 expres-
sion at the time of morphological change at 
relapse. 
All cases were positive for CD13 and CD33, and 
negative for HLA-DR.
Discussion
Although ATRA combined with anthracycline-
based chemotherapy yields a complete remis-
sion rate of approximately 90% for newly-diag-
Figure 1. Bone marrow aspirate smears of acute promyelocytic leukemia. A: Typical macrogranular neoplastic pro-
myelocytes (Case 3 at initial diagnosis). The leukemic cells have bi-lobed or folded nuclei and abundant cytoplasm 
with large granules. Wright-Giemsa, × 1,000. B: Microgranular variant of acute promyelocytic leukemia (Case 12). 
The leukemic cells have bi-lobed or folded nuclei and inconspicuous cytoplasmic granules. Wright-Giemsa, × 400. 
C: Case 3 at the second relapse. The leukemic cells have a high nuclear/cytoplasmic ratio, scant cytoplasm, and ir-
regular nuclear contours. The cytoplasm of these cells contains no granules, although small vacuoles are present in 
some. Wright-Giemsa, × 1,000. D: Case 4 at the third relapse. The leukemic cells have a small amount of cytoplasm 
and irregular nuclear contours, and contain no granules. Wright-Giemsa, × 1,000.
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nosed APL, relapse frequently occurs (approxi-
mately 20%). The approach for establishing the 
diagnosis of relapse in APL relies on the pre-
sumption that recurrent disease will have mor-
phology similar to pre-therapy appearance. 
Dimov et al. reported that the morphological 
type of leukemic cells at relapse in APL is usu-
ally stable over time. However, they did find that 
one of 38 relapsed cases (2.6%) showed a mor-
phological change [7]. That case was a typical 
macrogranular type at initial diagnosis before 
therapy and relapsed as M3v, having blastic 
features with scant cytoplasm and no granules 
in the cytoplasm [7]. In our study, 2 of 4 cases 
of relapsed APL manifested morphological 
change at the time of relapse, and the leukemic 
cells had different morphological features in 
each case. At the second relapse of Case 3, the 
leukemic cells had a high nuclear/cytoplasmic 
ratio and scant cytoplasm, resembling myelo-
blasts. These are the same morphological fea-
tures as the previously reported case by Dimov 
et al. [7]. The leukemic cells at the third relapse 
of Case 4 had a small amount of cytoplasm and 
irregular nuclear contours, and were therefore 
akin to monocytoid leukemic cells. Cytogenetic 
analyses revealed the continued presence of 
t(15;17)(q22;q12) in these two cases at relapse. 
Therefore, the leukemic cells with a changed 
morphology were considered to be relapsed 
APL. These findings indicate that the morpho-
logical change from typical macrogranular type 
to M3v at relapse may not be such a rare event, 
so that these morphological characteristics at 
relapse might lead to misdiagnosis as a differ-
ent type of AML, such as M0, M1, M4, or M5. 
Additionally, the development of t-MN can occur 
in patients successfully treated for APL [9, 10]. 
Case 10 of the present series developed MDS 
after ATRA therapy. Because the neoplastic 
cells were CD34+/HLA-DR+, and lacked t(15;17)
(q22;q12), this case was diagnosed as t-MN 
secondary to APL. According to previous stud-
ies, although MDS is the most common disease 
of t-MN secondary to APL, AML including M0, 
M1, M4, and M5 has also been recognized as 
t-MN [9, 10]. Therefore, t-MN must be distin-
guished from relapsed APL showing morpho-
logical change, because the latter can manifest 
similar morphological features as M0, M1, M4, 
and M5, as seen in the present Cases 3 and 4, 
and previously reported [7]. Thus, cytogenetic 
analysis is needed for the correct diagnosis of 
relapsed APL. Moreover, because therapies for 
relapsed APL and t-MN secondary to APL are 
completely different, this differential diagnosis 
is crucial. 
Typical neoplastic promyelocytes characteristi-
cally express mature myeloid markers, includ-
Table 2. Morphological and immunophenotypic characteristics of acute promylocytic leukemia
Case No. Morphology CD2 CD34 CD56 CD13 CD33 HLA-DR
Group I (M3 with relapse)
1 (initial) Macrogranular 33 34 2 96 99 8
2 (relapsed, 1st) Macrogranular 1 2 58 53 92 6
3 (initial) Macrogranular 1 1 0 58 95 2
(relapsed, 2nd) Microgranular 76 66 7 99 99 11
4 (initial) Macrogranular 4 6 2 74 86 11
(relapsed, 3rd) Microgranular 85 90 21 86 98 10
Group II (M3 with complete remission)
5 Macrogranular 0 1 ND 65 96 1
6 Macrogranular 0 0 0 30 98 15
7 Macrogranular 1 1 0 75 98 2
8 Macrogranular 0 0 0 60 91 0
9 Macrogranular 9 4 1 86 87 5
10 Macrogranular 7 16 3 96 99 2
11 Macrogranular 11 4 ND 74 79 8
Group III (M3v)
12 Microgranular 51 8 23 95 98 9
ND, Not done.
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ing CD13 and CD33, and are usually negative 
for CD2 (12%), CD34 (0%), and HLA-DR (1%) [2, 
3]. However, M3v is more heterogeneous with 
variable expression of CD2 (56%), CD34 (75%), 
and HLA-DR (31%), although CD13 and CD33 
are also expressed in M3v [3]. Although the 
immune phenotype of the leukemic cells at 
relapse was unchanged in the previously 
reported case despite the morphological 
change from typical macrogranular type at ini-
tial diagnosis to M3v at relapse (the detailed 
immune phenotype was not available) [7], we 
saw clear expression of CD2 and CD34 at 
relapse in the cases showing morphological 
change (Cases 3 and 4). This might be related 
to the change of morphological features of leu-
kemic cells in APL because CD2 and CD34 are 
commonly expressed in M3v, but not in macro-
granular type. 
In summary, this study revealed that morpho-
logical changes of leukemic cells at relapse in 
APL may not a rare event, and that the leukemic 
cells can show variable morphological features 
resembling myeloblasts or monocytoid leuke-
mic cells. It is difficult to estimate by morpho-
logical, immunophenotypic, and risk-of-relapse 
analysis at initial diagnosis whether the mor-
phological features will change or not at the 
time of relapse. Given the risk of misinterpreta-
tion, a comprehensive approach with emphasis 
on combined morphological, immunophenotyp-
ic, and cytogenetic analysis is important for the 
diagnosis and correct treatment of relapsed 
APL. 
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